FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Brief summary

This is a prospective, open-label, randomized, phase III trial. Patients will be stratified after breast surgery, as per investigational site; menopausal status; node negative diagnosis, as per sentinel-node technique versus lymphadenectomy; hormone receptor status (positive versus negative).

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

status

COMPLETED

phase

PHASE3

study type

INTERVENTIONAL

enrollment

1925

sponsor

Spanish Breast Cancer Research Group

conditions

Breast Cancer

interventions

DRUG: Fluorouracil; DRUG: Doxorubicin; DRUG: Cyclophosphamide; DRUG: Paclitaxel

start date

2003-09-19

start date type

ACTUAL

primary completion date

2013-10-01

has results

true

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters